Comparing 5% Dextrose Injections Into or Around Partial Supraspinatus Tendon Tears
Intralesional Versus Perilesional 5% Dextrose Injection for Partial Supraspinatus Tendon Tears: A Randomized Controlled Trial
This prospective, single-center randomized trial compared ultrasound-guided intralesional and perilesional 5% dextrose injections in adults with partial supraspinatus tendon tears. Participants and outcome assessors were blinded to group assignment. Forty-six participants were randomized equally to the two groups, and 40 completed follow-up and were included in the final analysis (20 per group).
Both groups received ultrasound-guided injections at baseline and at study weeks 3 and 6. At each session, both groups received a 5% dextrose injection at the supraspinatus tendon attachment. An additional injection was given either directly into the tear or into the tendon tissue around it, depending on group assignment. Both groups began the same home exercise program after the first injection.
Shoulder pain, disability, and health-related quality of life were assessed at baseline and at study weeks 9 and 12. Tear dimensions and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.
調査の概要
状態
詳細な説明
This prospective, single-center, parallel-group randomized trial enrolled adults aged 18 to 75 years with symptomatic partial supraspinatus tendon tears. An independent researcher generated the 1:1 allocation sequence using a computer-based random number generator. Allocation was concealed in sequentially numbered, opaque, sealed envelopes. The injecting physician opened the envelopes after the baseline clinical and ultrasonographic assessments. Participants and outcome assessors were blinded to group assignment.
Both groups received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, 2 mL was distributed across three points at the supraspinatus tendon enthesis in both groups. An additional 2 mL was injected into the tendon defect in the intralesional group or into the tendon tissue surrounding the defect in the perilesional group using a peppering technique. The total injection volume was 4 mL per session in both groups. Participants began the same standardized home exercise program after the first injection and were instructed to perform it twice daily throughout the study.
Clinical outcomes were assessed at baseline and at study weeks 9 and 12. Mean daytime pain, worst daytime pain, and night pain were recorded separately using the Numeric Rating Scale. Shoulder pain and disability were assessed using the Shoulder Pain and Disability Index, and health-related quality of life was assessed using the 12-Item Short Form Health Survey. Short-axis and long-axis defect diameters and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Ankara、トルコ(Türkiye)
- Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18 to 75 years
- Shoulder pain and functional limitation for at least 3 months
- Partial supraspinatus tendon tear identified on magnetic resonance imaging performed within the previous 6 months and confirmed by ultrasonography at study entry. Articular-sided, bursal-sided, and intrasubstance tears were eligible.
- At least one positive Neer, Hawkins-Kennedy, or painful arc test
- Ability to attend follow-up visits
- Written informed consent to participate
For participants with bilateral involvement, only the more painful shoulder was included.
Exclusion Criteria:
- - Full-thickness supraspinatus tendon tear
- Major pathology of rotator cuff tendons other than the supraspinatus
- Advanced acromioclavicular or glenohumeral osteoarthritis
- Marked adhesive capsulitis
- Previous shoulder surgery
- Corticosteroid, platelet-rich plasma, or prolotherapy injection into the affected shoulder within the previous 3 months
- Active infection, including infection at the injection site
- Skin lesion at the injection site
- Bleeding diathesis or anticoagulant use
- Known allergy or intolerance to dextrose
- Uncontrolled diabetes mellitus (HbA1c >8.5%)
- Severe endocrine or metabolic disease
- Immunosuppression
- Rheumatologic disease involving the shoulder
- Neurological disease affecting shoulder function
- Pregnancy
- Active malignancy
- Cognitive impairment preventing reliable completion of questionnaires
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Intralesional 5% Dextrose Injection
Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and directly into the partial tendon tear. Participants began the same standardized home exercise program as the perilesional group after the first injection. |
At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected directly into the partial tendon defect using a peppering technique. The total volume was 4 mL per session. |
|
アクティブコンパレータ:Perilesional 5% Dextrose Injection
Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and into the tendon tissue surrounding the margins of the partial tear. Participants began the same standardized home exercise program as the intralesional group after the first injection. |
At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected into the tendon tissue surrounding the margins of the partial tear using a peppering technique. The total volume was 4 mL per session. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Shoulder Pain Intensity Assessed by Numeric Rating Scale
時間枠:Baseline and study weeks 9 and 12.
|
Mean daytime shoulder pain, worst daytime shoulder pain, and night pain were assessed separately using an 11-point Numeric Rating Scale (NRS). Each score ranged from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicated greater pain intensity. |
Baseline and study weeks 9 and 12.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability Index
時間枠:Baseline and study weeks 9 and 12.
|
The Shoulder Pain and Disability Index (SPADI) was used to assess shoulder pain and disability. The pain subscale contains 5 items, and the disability subscale contains 8 items. The two subscales were scored separately on a 0-100 scale. Higher scores indicated greater pain or disability. |
Baseline and study weeks 9 and 12.
|
|
Change in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey
時間枠:Baseline and study weeks 9 and 12.
|
Health-related quality of life was assessed using the 12-Item Short Form Health Survey (SF-12). The Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated separately. Higher scores indicated better health-related quality of life in the corresponding component. |
Baseline and study weeks 9 and 12.
|
|
Change in Supraspinatus Tendon Thickness Assessed by Ultrasonography
時間枠:Baseline and study week 12.
|
Supraspinatus tendon thickness was measured in millimeters using shoulder ultrasonography with a 5-12 MHz linear transducer. |
Baseline and study week 12.
|
|
Change in Partial Rotator Cuff Defect Size Assessed by Ultrasonography
時間枠:Baseline and study week 12.
|
The short-axis and long-axis diameters of the partial supraspinatus tendon tear were measured separately in millimeters using electronic calipers on the ultrasound images that best displayed the defect. |
Baseline and study week 12.
|
協力者と研究者
捜査官
- 主任研究者:ESRA Ülgen Kıratlıoğlu、Ankara City Hospital Bilkent
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- E2-26-14590
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be shared due to privacy and ethical restrictions.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。